Discontinuation due to immune‐related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non‐small cell lung cancer

BACKGROUND: Immune‐related adverse events (irAEs) should be anticipated with treatment by immune checkpoint inhibitors (ICIs). Although the relationship between irAEs and efficacy of ICI has been reported, it has not yet been clarified whether the benefit from ICI outweighs the low frequency of proc...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Thorac Cancer
Autori principali: Komiya, Kazutoshi, Nakamura, Tomomi, Abe, Tomonori, Ogusu, Shinsuke, Nakashima, Chiho, Takahashi, Koichiro, Kimura, Shinya, Sueoka‐Aragane, Naoko
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons Australia, Ltd 2019
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718019/
https://ncbi.nlm.nih.gov/pubmed/31328416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13149
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi